Insulin Lispro

Insulin lispro is a rapid‑acting insulin analog used to manage hyperglycemia in the diabetes mellitus disease family.

• Type 1 diabetes mellitus: provides mealtime glucose control and reduces post‑prandial blood glucose excursions.
• Type 2 diabetes mellitus: assists in achieving glycemic targets when combined with oral agents or basal insulin.

• Insulin lispro binds to the α‑subunit of the insulin receptor on muscle, adipose and hepatic cells, activating the intrinsic tyrosine kinase. This triggers downstream signaling that promotes translocation of GLUT‑4 transporters, increasing glucose uptake, while suppressing hepatic gluconeogenesis, resulting in rapid reduction of circulating glucose after injection. Its single amino‑acid substitution from human insulin gives it a faster onset and shorter duration compared with regular insulin.

Insulin lispro may cause adverse reactions ranging from mild to severe.

Common Side Effects

• Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive.
• Injection site pain or erythema: mild discomfort or redness at the injection site.
• Lipodystrophy: localized thickening or loss of subcutaneous fat with repeated injections.
• Weight gain: modest increase in body weight due to improved glucose utilization.
• Edema: mild swelling of extremities.

Serious or Rare Side Effects

• Severe hypoglycemia: neurological symptoms requiring immediate assistance.
• Allergic reaction: rash, urticaria, or angioedema.
• Anaphylaxis: rare life‑threatening systemic hypersensitivity.
• Hypokalemia: low potassium levels, particularly with high doses.
• Acute insulin resistance: sudden loss of insulin effect.

When using insulin lispro, several precautions should be observed to ensure safety and efficacy.

• Dose individualization: titrate based on blood glucose monitoring and clinical response.
• Hypoglycemia risk: educate patients on recognizing and treating low blood glucose.
• Concomitant medications: adjust dose when using agents that affect glucose levels (e.g., sulfonylureas).
• Pregnancy: classified as Category B; use only if benefits outweigh potential risks.
• Renal or hepatic impairment: monitor closely and consider dose adjustments.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro can interact with other medicines, altering its glucose‑lowering effect or increasing adverse events.

Major Interactions (Avoid)

• Beta‑blockers: may mask hypoglycemia symptoms and prolong its duration.
• Monoamine oxidase inhibitors (MAOIs): can potentiate hypoglycemic effect.
• Alcohol: enhances insulin action and increases risk of severe hypoglycemia.

Moderate Interactions (Monitor Closely)

• Sulfonylureas or meglitinides: additive glucose‑lowering effect may require dose reduction.
• Corticosteroids: may increase insulin requirements.
• Thyroid hormones: can affect insulin metabolism and glucose control.
• Diuretics (loop/thiazide): may cause electrolyte shifts influencing insulin action.